

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ADQUEY safely and effectively. See full prescribing information for ADQUEY.

ADQUEY™ (difamilast) ointment, for topical use  
Initial U.S. Approval: 2026

### INDICATIONS AND USAGE

ADQUEY is a phosphodiesterase 4 inhibitor indicated for the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis. (1)

### DOSAGE AND ADMINISTRATION

- For topical use only. Not for ophthalmic, oral, or intravaginal use. (2)
- Apply a thin layer of ADQUEY twice daily to affected areas and rub in completely. (2)

### DOSAGE FORMS AND STRENGTHS

Ointment: 1%. (3)

### CONTRAINDICATIONS

None. (4)

### ADVERSE REACTIONS

The most common adverse reaction occurring in  $\geq 1\%$  of subjects is nasopharyngitis. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Acrotech Biopharma Inc. at 1-888-292-9617 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

See 17 for PATIENT COUNSELING INFORMATION

Revised: 02/2026

## FULL PRESCRIBING INFORMATION: CONTENTS\*

<b>1</b>	<b>INDICATIONS AND USAGE</b>	<b>12</b>	<b>CLINICAL PHARMACOLOGY</b>
<b>2</b>	<b>DOSAGE AND ADMINISTRATION</b>	12.1	Mechanism of Action
<b>3</b>	<b>DOSAGE FORMS AND STRENGTHS</b>	12.2	Pharmacodynamics
<b>4</b>	<b>CONTRAINDICATIONS</b>	12.3	Pharmacokinetics
<b>6</b>	<b>ADVERSE REACTIONS</b>	<b>13</b>	<b>NONCLINICAL TOXICOLOGY</b>
6.1	Clinical Trial Experience	13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility
6.2	Postmarketing Experience	<b>14</b>	<b>CLINICAL STUDIES</b>
<b>8</b>	<b>USE IN SPECIFIC POPULATIONS</b>	<b>15</b>	<b>REFERENCES</b>
8.1	Pregnancy	<b>16</b>	<b>HOW SUPPLIED/STORAGE AND HANDLING</b>
8.2	Lactation	<b>17</b>	<b>PATIENT COUNSELING INFORMATION</b>
8.4	Pediatric Use		
8.5	Geriatric Use		
<b>11</b>	<b>DESCRIPTION</b>		

\*Sections or subsections omitted from the full prescribing information are not listed.

## **FULL PRESCRIBING INFORMATION**

### **1 INDICATIONS AND USAGE**

ADQUEY is indicated for the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis.

### **2 DOSAGE AND ADMINISTRATION**

ADQUEY is for topical use only and not for ophthalmic, oral, or intravaginal use.

Apply a thin layer of ADQUEY twice daily to affected areas and rub in completely.

Wash hands after application.

Avoid areas of the skin that are infected when applying ADQUEY.

### **3 DOSAGE FORMS AND STRENGTHS**

Ointment: 1% (10 mg of difamilast per gram) of white to off-white ointment.

### **4 CONTRAINDICATIONS**

None.

### **6 ADVERSE REACTIONS**

#### **6.1 Clinical Trial Experience**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of ADQUEY was assessed in two double-blind, vehicle-controlled clinical trials (Trial 2 and Trial 3) that enrolled 532 adult and pediatric subjects 2 years of age and older in Japan with mild to moderate atopic dermatitis (AD). Subjects applied ADQUEY or vehicle ointment topically twice daily for 4 weeks [see *Clinical Studies (14)*]. Adverse reactions reported by  $\geq 1\%$  of ADQUEY-treated subjects and more frequently than in subjects receiving vehicle are listed in Table 1.

**Table 1: Adverse Reactions Occurring in  $\geq 1\%$  of Adult and Pediatric Subjects 2 Years of Age and Older Treated with ADQUEY for Mild to Moderate Atopic Dermatitis (and Greater than Vehicle) through Week 4 in Trials 2 and 3**

Adverse Reaction	ADQUEY (N=267) n (%)	Vehicle (N=265) n (%)
Nasopharyngitis	16 (6)	10 (4)

Less common ( $<1\%$ ) adverse reactions in subjects treated with ADQUEY in Trials 2 and 3 included application site folliculitis, contact dermatitis, application site rash, and molluscum contagiosum.

In Trial 1, a vehicle-controlled dose ranging trial, 43 subjects 10 years of age and older in the United States, Australia, and Poland received ADQUEY topically twice daily for 8 weeks and the safety profile was consistent with Trials 2 and 3.

In two additional vehicle-controlled dose ranging trials (Trial 4 and Trial 5), 92 subjects 2 years of age and older in Japan received ADQUEY topically twice daily for 4 weeks (Trial 4) and twice daily for 8 weeks (Trial 5) and the safety profile was consistent with Trials 2 and 3.

In open-label trials of both Japanese and United States (US) subjects, 857 adult and pediatric subjects continued twice-daily treatment with ADQUEY for up to 52 weeks. The following application site adverse reactions occurred that led to drug discontinuation: pain, pruritus, vesicles, blistering, erythema, burning and contact dermatitis.

## 6.2 Postmarketing Experience

The following adverse reactions have been identified during post approval use of ADQUEY. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

*General disorders and administration site condition:* application site swelling.

## 8 USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

#### Risk Summary

The available data on the use of topical difamilast during pregnancy are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

In animal reproduction studies, difamilast administered subcutaneously to pregnant rats and rabbits during the period of organogenesis produced no fetal structural abnormalities at doses up to 30 and 3 times the maximum recommended human dose (MRHD), respectively. Difamilast

induced increased post-implantation loss, decreased fetal weight, retarded ossification and increased visceral abnormalities in rats at subcutaneous dose 263 times the MRHD. Difamilast induced increased skeletal variations in rabbits at subcutaneous doses 14 times the MRHD (*see Data*). The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defects, loss, and other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

## Data

### *Animal Data*

In an embryo-fetal development study, pregnant rats were dosed subcutaneously during the period of organogenesis with up to 100 mg/kg/day difamilast (263 times the MRHD based on AUC comparison). Increased post-implantation loss, decreased fetal weight, retarded ossification, and increased visceral abnormalities (membranous ventricular septum defect) were noted at 100 mg/kg/day (263 times the MRHD based on AUC comparison). No embryo-fetal toxicity was observed at 10 mg/kg/day (30 times the MRHD based on AUC comparison).

In an embryo-fetal development study in rabbits, pregnant does were dosed subcutaneously during the period of organogenesis with up to 3 mg/kg/day difamilast (14 times the MRHD based on AUC comparison). Increased skeletal variations (increased supernumerary lumbar vertebra) were observed at 3 mg/kg/day (14 times the MRHD based on AUC comparison). No embryo-fetal toxicity was observed at 1 mg/kg/day (3 times the MRHD based on AUC comparison).

In a pre- and post-natal development study in rats, dams were dosed subcutaneously with up to 3 mg/kg/day difamilast during the periods of organogenesis and lactation. No treatment-related adverse effects on reproductive functions of dams, or pre- and post-natal development of offspring were observed at 3 mg/kg/day (13 times the MRHD based on AUC comparison).

## **8.2 Lactation**

### Risk Summary

There are no data on the presence of difamilast or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.

Difamilast and/or its metabolites are excreted into the milk of lactating rats (*see Data*). When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ADQUEY and any potential adverse effects on the breastfed infant from ADQUEY or from the underlying maternal condition.

### Clinical Considerations

To minimize potential infant exposure, advise breastfeeding women not to apply ADQUEY directly to the nipple or areola. If applied to the patient's chest, avoid exposure via direct contact with the infant's skin.

## Data

When  $^{14}\text{C}$ -difamilast was subcutaneously administered to lactating rats at a single dose of 3 mg/kg, the concentration of radioactivity in milk was higher than that in blood (with milk/blood ratios at  $C_{\text{max}}$  and  $\text{AUC}_{\infty}$  of 13.7 and 5.4, respectively). The concentration of difamilast in animal milk does not necessarily predict the concentration of drug in human milk.

## 8.4 Pediatric Use

The safety and effectiveness of ADQUEY for the topical treatment of mild to moderate atopic dermatitis have been established in pediatric patients 2 years of age and older. Use of ADQUEY in this age group is supported by data from five vehicle-controlled trials, which included 236 subjects 2 to less than 17 years of age, of whom 119 received ADQUEY and 117 received vehicle [see *Adverse Reactions* (6.1), *Clinical Pharmacology* (12.3) and *Clinical Studies* (14)].

The safety and effectiveness of ADQUEY have not been established in pediatric patients younger than 2 years of age.

## 8.5 Geriatric Use


In clinical trials of ADQUEY in subjects with mild to moderate atopic dermatitis, 2 subjects were 65 years of age or older, and 0 were aged 75 years and older. Clinical trials of ADQUEY did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger adult subjects.

## 11 DESCRIPTION

ADQUEY (difamilast) ointment contains difamilast as the active ingredient. Difamilast, is a phosphodiesterase-4 (PDE-4) inhibitor.

Difamilast is described chemically as N-({2-[4-(Difluoromethoxy)-3-(propan-2-yloxy)phenyl]-1,3-oxazol-4-yl}methyl)-2-ethoxybenzamide. The empirical formula is  $\text{C}_{23}\text{H}_{24}\text{F}_2\text{N}_2\text{O}_5$  and the molecular weight is 446.44 g/mol.

The structural formula is represented below:



Difamilast occurs as white (or practically white) crystals or crystalline powder. It is very soluble in N-methylpyrrolidone, freely soluble in methanol and ethanol (99.5), and practically insoluble in water. It shows crystal polymorphism.

Each gram of ADQUEY contains 1% difamilast (w/w) in a wax-based, white to off-white ointment containing the following inactive ingredients: mineral oil, paraffin, propylene carbonate, white petrolatum, and white wax.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

Difamilast is an inhibitor of phosphodiesterase-4 (PDE-4). Difamilast's inhibition of PDE-4 (a major cyclic adenosine monophosphate (AMP)-metabolizing enzyme) activity leads to accumulation of intracellular cyclic AMP and decreased productions of various cytokines and chemokines. However, the specific mechanism(s) by which difamilast exerts its therapeutic action is not well defined.

### 12.2 Pharmacodynamics

The pharmacodynamics of ADQUEY ointment in the treatment of atopic dermatitis is not known.

#### Cardiac Electrophysiology

ADQUEY ointment is not expected to cause clinically significant QTc interval prolongation at the recommended dosages.

### 12.3 Pharmacokinetics

#### Absorption

The pharmacokinetics (PK) of ADQUEY were investigated in 31 pediatric subjects 2 years of age and older with moderate to severe atopic dermatitis and a mean  $\pm$  SD body surface area (BSA) involvement of  $44 \pm 13\%$  (range 25% to 80%). In this trial, subjects applied an average of approximately 4.3 g of ADQUEY ointment, 1% (dose range was 1.7 to 11.7 g per application) twice daily for 2 weeks.

Plasma concentrations were quantifiable in all the subjects. On Day 15, the mean  $\pm$  SD maximum plasma concentration ( $C_{max}$ ) and area under the concentration time curve from 0 to 8 hours post dose ( $AUC_{0-8}$ ) for difamilast were  $16.9 \pm 21.9$  ng/mL and  $86.2 \pm 79.6$  ng\*h/mL, respectively. Systemic concentrations of difamilast were at steady state by Day 15, with no evidence of accumulation.

The PK of ADQUEY were investigated in 31 adult subjects with mild to moderate atopic dermatitis and a mean  $\pm$  SD BSA involvement of  $6 \pm 3\%$  (range 3% to 19%). Subjects applied an average of approximately 0.9 g of ADQUEY ointment, 1% (dose range was 0.1 to 3.8 g per application) twice daily for 4 weeks. On Day 29, the mean  $\pm$  SD  $C_{max}$  and  $AUC_{0-12}$  for difamilast were  $0.76 \pm 1.16$  ng/mL and  $6.10 \pm 8.85$  ng\*h/mL, respectively.

#### Distribution

Difamilast serum protein binding is 99% and is not concentration-dependent, in vitro.

#### Elimination

#### *Metabolism*

Difamilast is substantially metabolized to form three major metabolites in the plasma via CYP3A4-mediated O-deethylation (Metabolite 1), CYP1A2-mediated hydroxylation (Metabolite 2), and enzymatic hydrolysis (Metabolite 3).

#### *Excretion*

After both single dosing and twice daily administration of difamilast ointment 1% in healthy Japanese subjects for 2 weeks, difamilast and Metabolite 1 were undetectable in urine. The urinary excretion ratios of all the other metabolites were less than 0.1% of the administered dose.

#### Specific Populations

No dedicated clinical trials have been conducted to assess the impact of intrinsic factors on the PK of difamilast. Based on cross-study analyses, no substantial differences in the PK of difamilast were observed based on age (2-70 years), sex, race, mild or moderate renal impairment, or mild or moderate hepatic impairment. The effect of severe renal impairment (eGFR < 30 mL/min), or severe (Child-Pugh Class C) hepatic impairment on difamilast PK is unknown.

#### *Pediatric Patients*

The plasma difamilast trough concentration corrected by dose in pediatric patients was 1.3 to 1.9 times higher than that in adults (on Day 1 and Day 15, respectively).

#### Drug Interaction Studies

##### *Clinical Studies*

No clinical drug interaction trials have been conducted with topical difamilast.

##### *In Vitro Studies*

*CYP450 Enzymes:* Difamilast is a substrate of CYP3A4 and CYP1A2. Difamilast is not expected to inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 at clinically relevant concentrations. Induction of CYP1A2, CYP2B6, CYP2C9, and CYP3A4 by difamilast is expected to be low at clinically relevant concentrations.

*Transporter Systems:* Difamilast is a substrate of breast cancer resistance protein (BCRP), but is not a substrate of P-glycoprotein (P-gp), OATP1B1, or OATP1B3. Difamilast is not expected to inhibit P-gp, BCRP, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, or MATE2-K at clinically relevant concentrations.

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

In a 2-year dermal carcinogenicity study in rats, no test article-related neoplastic findings were observed in male or female rats that received difamilast at dermal doses up to 3% ointment applied at 0.008 ml/cm<sup>2</sup> (4 times the MRHD based on AUC comparison).

In a 2-year dermal carcinogenicity study in mice, no test article-related neoplastic findings were observed in male or female mice that received difamilast at dermal doses up to 3% ointment applied at 0.008 ml/cm<sup>2</sup> (4 times the MRHD based on AUC comparison).

Difamilast was not genotoxic in an in vitro bacterial reverse mutation (Ames) test, an in vitro mammalian cell mutation test in mouse lymphoma cells, or an in vivo rat bone marrow micronucleus test.

In a fertility and early embryonic development study in rats, irregular estrus cycles, sperm abnormalities, increased preimplantation loss, and decreased copulation and fertility indexes were observed at a subcutaneous dose of 100 mg/kg/day difamilast (116 times the MRHD for males and 263 times the MRHD for females, respectively, based on AUC comparison). No treatment-related adverse effects on fertility or early embryonic development were observed at 10 mg/kg/day for males and females (20 times the MRHD for males and 30 times the MRHD for females, respectively, based on AUC comparison).

## 14 CLINICAL STUDIES

The efficacy of ADQUEY for the treatment of mild to moderate atopic dermatitis was assessed in three multicenter, randomized, double-blind, parallel-group, vehicle-controlled trials (Trial 1 [NCT02068352], Trial 2 [NCT03908970], and Trial 3 [NCT03911401]) that treated a total of 612 subjects. Trial 1 enrolled adult and pediatric subjects 10 years of age and older in the United States, Australia, and Poland. Trial 2 enrolled adult and pediatric subjects 15 years of age and older in Japan, and Trial 3 enrolled pediatric subjects 2 to 14 years of age in Japan. In these trials, subjects were randomized 1:1 to receive ADQUEY or vehicle ointment, applied topically to the entire treatment area twice daily for at least 4 weeks.

The trials enrolled subjects with an Investigator's Global Assessment (IGA) score of 2 (mild) or 3 (moderate) atopic dermatitis and affected body surface area (BSA) (excluding the face, neck, and head [Trial 1]; excluding the scalp [Trials 2 and 3]) of  $\geq 5\%$  and  $\leq 40\%$ . The IGA included an overall assessment of atopic dermatitis (erythema, induration/papulation, and oozing/crusting) on a severity scale of 0 to 4.

At baseline, 29%, 15%, and 15% of the subjects had an IGA of mild, and 71%, 85%, and 85% had an IGA of moderate in Trials 1, 2, and 3, respectively. Concomitant treatment for atopic dermatitis was prohibited.

In Trial 1, 56% of the subjects were female, 73% were White, 20% were Black or African American, and 4% were Asian; for ethnicity, 18% of the subjects identified as Hispanic or Latino. In Trials 2 and 3, the majority of the subjects were male (54% in Trial 2 and 58% in Trial 3), 100% were Asian, and 100% identified as Not Hispanic or Latino. The median age of enrolled subjects at baseline was 30 years (range 10 to 67 years), 30 years (range 15 to 65 years), and 7 years (range 2 to 14 years) in Trials 1, 2, and 3, respectively.

The primary efficacy endpoint for all trials was the proportion of subjects who achieved IGA success, defined as an IGA grade of clear (0) or almost clear (1) and with a 2-grade or greater improvement from baseline, at Week 4.

The efficacy results at Week 4 are shown in [Table 2](#).

**Table 2: Efficacy Results at Week 4 in Adult and Pediatric Subjects 2 Years of Age and Older with Mild to Moderate Atopic Dermatitis in Trials 1, 2, and 3**

	Trial 1 (Multinational <sup>‡</sup> )		Trial 2 (Japan)		Trial 3 (Japan)	
	ADQUEY (N = 43)	Vehicle (N = 37)	ADQUEY (N = 182)	Vehicle (N = 182)	ADQUEY (N = 85)	Vehicle (N = 83)
<b>IGA Success<sup>†</sup>, n (%)</b>	9 (21)	1 (3)	70 (38)	23 (13)	40 (47)	15 (18)
Difference, % from Vehicle (95% CI)	18 (5, 31)		26 (17, 34)		29 (15, 42)	

<sup>†</sup> IGA success is defined as an IGA score of 0 or 1 and with  $\geq 2$ -grade improvement from baseline.

<sup>‡</sup> Trial 1 enrolled subjects from the United States, Australia, and Poland.

Subjects with missing IGA scores were imputed as failures.

## 16 HOW SUPPLIED/STORAGE AND HANDLING

### How supplied

ADQUEY (difamilast) ointment, 1% is a white to off-white ointment supplied in the following packages:

- 27 g tube (NDC 72893-017-08)
- 85 g tube (NDC 72893-017-09)

### Storage and Handling

Store at 20°C–25°C (68°F–77°F); excursions permitted to 15°C–30°C (59°F–86°F). [see USP Controlled Room Temperature].

Store away from direct sunlight, heat, and moisture.

Keep tube tightly closed.

## 17 PATIENT COUNSELING INFORMATION

Advise patients or caregivers to read the FDA-approved patient labeling (Patient Information).

### Administration

Advise patients or caregivers that ADQUEY is for topical use only and is not for ophthalmic, oral, or intravaginal use [see *Dosage and Administration (2)*].

### Lactation

Advise breastfeeding women not to apply ADQUEY directly to the nipple or areola to minimize potential infant exposure. Instruct patients to avoid inadvertent contact of treated areas with the infant's skin [see *Use in Specific Populations (8.2)*].

(Made in Canada)

Manufactured for:  
Acrotech Biopharma Inc  
East Windsor, NJ 08520 USA